YFY Biotech Management Company, established in 2003, serves as the corporate venture capital arm of Yuen Foong Yu Paper Manufacturing Company in Taipei, Taiwan. The company concentrates on the bio-pharmaceutical, diagnostics, medical device, and healthcare technology sectors. YFY Biotech specializes in various investment stages, including incubation, seed and startup funding, as well as early and later-stage investments, alongside growth and buyout opportunities. Its strategic focus enables it to support innovative companies and technologies within the life sciences field, contributing to advancements in healthcare solutions.
Omni-ID Ltd. specializes in developing passive ultra high frequency radio frequency identification (RFID) technology products that are designed for efficient asset tracking and management. The company offers a range of RFID tags, including the Max and Flex tags for various applications such as conveyance, industrial devices, and retail shelving. Additionally, Omni-ID provides the Prox tag for IT asset identification and the ProVIEW system, which combines visual instructions with RFID tracking and process communication software. Their products are engineered to perform reliably in challenging environments, including those involving metals and liquids, ensuring accurate identification of high-value assets. Founded in 2007 and based in Farnham, United Kingdom, Omni-ID serves diverse sectors including information technology, telecommunications, industrial, and retail markets, focusing on cost-effective solutions for tagging, tracking, and monitoring applications.
TaiGen Biotechnology
Series C in 2009
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company based in Taipei, Taiwan, with operations extending to China and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of novel therapeutics aimed at treating infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug targeting community-acquired pneumonia and various skin infections; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, a treatment for influenza A and B. Additionally, TaiGen develops stem cell mobilizers for leukemia treatment and offers a range of antiviral and antibacterial agents. The company operates as a subsidiary of Taigen Biopharmaceuticals Holdings Limited.
TaiGen Biotechnology
Series B in 2004
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company based in Taipei, Taiwan, with operations extending to China and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of novel therapeutics aimed at treating infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug targeting community-acquired pneumonia and various skin infections; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, a treatment for influenza A and B. Additionally, TaiGen develops stem cell mobilizers for leukemia treatment and offers a range of antiviral and antibacterial agents. The company operates as a subsidiary of Taigen Biopharmaceuticals Holdings Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.